CFI-400945 shows significant antitumor activity in various lymphoma models [52, 78, 81]. In diffuse large B-cell lymphoma (DLBCL), the combination of CFI-400945 with doxorubicin markedly delays tumor progression in DLBCL xenografts [52]. A BCL-2 (B cell lymphoma 2) inhibitor, venetoclax, in combination with CFI-400945 overcomes the drug resistance and leads to a strong synergistic antitumor effect in lymphoma models [81]. This evidence concerns the gene BCL2 and neoplasm.